An Open-Label Pilot Study of OLILIV Juice to Assess Efficacy and Safety in Mild to Moderate Hepatic Dysfunctions

It’s an open-label, exploratory retrospective pilot study. The primary goal is to determine whether OLILIV Juice is effective in reducing liver enzymes (AST, ALT, AKP, GGT) from baseline to end of the study [Time Frame 8 weeks]. The single arm trial aims to recruit 24 participants who meet the selection criteria of presence of liver dysfunction symptoms (e.g., abdominal pain, fatigue, loss of appetite, right upper quadrant discomfort), AST and ALT greater than 40 IU per L, AST and ALT ratio greater than 0.8 or BARD score equal or greater than 2. The treatment will continue for 8 weeks with 30 ml of OLILIV Juice taken twice before meals. Before and after 8 weeks of treatment, the following examinations will be performed: BMI, Efficacy Blood Test (CRP, Platelet, FBG, HbA1c, Lipid profile, LFT, GGT), and Safety Assessments (CBC, LFT, BUN, Creatinine). The endpoint variables will be analyzed using Chi-square, t-test, 95 percent confidence interval, and ANOVA, as appropriate. P-values less than 0.05 will be considered statistically significant.